2,000 Patients Treated with OssDsign Catalyst in the U.S.

OssDsign Catalyst Bone Substitute

OssDsign’s Catalyst nanosynthetic bone graft has been used to treat 2,000 U.S. patients to date, up from 1,000 patients treated in May and 500 patients in January.

OssDsign Catalyst is designed to stimulate the formation of healthy bone tissue in spinal fusion surgeries. The graft is composed of a proprietary nanocrystalline structure...

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.

Contact Us